DK1686997T3 - Inhibitorer af mutantformen af KIT - Google Patents

Inhibitorer af mutantformen af KIT

Info

Publication number
DK1686997T3
DK1686997T3 DK04818795T DK04818795T DK1686997T3 DK 1686997 T3 DK1686997 T3 DK 1686997T3 DK 04818795 T DK04818795 T DK 04818795T DK 04818795 T DK04818795 T DK 04818795T DK 1686997 T3 DK1686997 T3 DK 1686997T3
Authority
DK
Denmark
Prior art keywords
kit
inhibitors
mutant form
mutant
administered
Prior art date
Application number
DK04818795T
Other languages
Danish (da)
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1686997T3 publication Critical patent/DK1686997T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK04818795T 2003-11-18 2004-11-17 Inhibitorer af mutantformen af KIT DK1686997T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
DK1686997T3 true DK1686997T3 (da) 2009-07-27

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04818795T DK1686997T3 (da) 2003-11-18 2004-11-17 Inhibitorer af mutantformen af KIT

Country Status (27)

Country Link
US (3) US8017621B2 (pl)
EP (2) EP1917965A1 (pl)
JP (3) JP4762150B2 (pl)
KR (1) KR101153647B1 (pl)
CN (3) CN101693031A (pl)
AT (1) ATE428426T1 (pl)
AU (1) AU2004290902B2 (pl)
BR (1) BRPI0416680A (pl)
CA (1) CA2546189C (pl)
CY (1) CY1110354T1 (pl)
DE (1) DE602004020654D1 (pl)
DK (1) DK1686997T3 (pl)
ES (1) ES2324917T3 (pl)
HR (1) HRP20090390T1 (pl)
IL (2) IL175578A (pl)
MA (1) MA28176A1 (pl)
MX (1) MXPA06005598A (pl)
NO (1) NO20062694L (pl)
NZ (1) NZ547195A (pl)
PL (1) PL1686997T3 (pl)
PT (1) PT1686997E (pl)
RU (2) RU2405553C1 (pl)
SG (1) SG139747A1 (pl)
SI (1) SI1686997T1 (pl)
TN (1) TNSN06138A1 (pl)
WO (1) WO2005049032A1 (pl)
ZA (1) ZA200603905B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CN101693031A (zh) 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
EP1879584B1 (en) 2005-05-02 2016-06-22 Novartis AG Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
CA2606716C (en) 2005-05-02 2013-07-23 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
WO2007010014A2 (en) * 2005-07-20 2007-01-25 Peter Valent Compositions for treatment of systemic mastocytosis
WO2007065898A1 (en) * 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
PL2237783T3 (pl) * 2008-01-23 2015-04-30 Novartis Ag Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu
EP3076966A2 (en) 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
US20220010382A1 (en) * 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pl) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE432078T1 (de) 1997-11-13 2009-06-15 Mowycal Lending Llc Kleine peptide und methoden zur behandlung von asthma und entzündungen
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
EP1401429A2 (en) 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
CA2478640A1 (en) * 2002-03-13 2003-09-18 F. Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
CN101693031A (zh) 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
CA2606716C (en) 2005-05-02 2013-07-23 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
IL175578A (en) 2013-10-31
TNSN06138A1 (fr) 2007-11-15
CA2546189A1 (en) 2005-06-02
NO20062694L (no) 2006-06-12
HRP20090390T1 (hr) 2009-08-31
JP2011121973A (ja) 2011-06-23
CN101693031A (zh) 2010-04-14
CN1882344A (zh) 2006-12-20
DE602004020654D1 (de) 2009-05-28
US20070213317A1 (en) 2007-09-13
EP1686997B1 (en) 2009-04-15
HK1093680A1 (en) 2007-03-09
MA28176A1 (fr) 2006-09-01
RU2362562C2 (ru) 2009-07-27
MXPA06005598A (es) 2006-08-11
US8124611B2 (en) 2012-02-28
SI1686997T1 (sl) 2009-08-31
ATE428426T1 (de) 2009-05-15
EP1917965A1 (en) 2008-05-07
ZA200603905B (en) 2008-11-26
JP2013241438A (ja) 2013-12-05
AU2004290902B2 (en) 2008-09-25
CN102274230B (zh) 2015-07-01
JP4762150B2 (ja) 2011-08-31
RU2009110449A (ru) 2010-09-27
PT1686997E (pt) 2009-07-17
RU2006121447A (ru) 2008-01-10
US20100179179A1 (en) 2010-07-15
SG139747A1 (en) 2008-02-29
JP2007511567A (ja) 2007-05-10
US20120157441A1 (en) 2012-06-21
EP1686997A1 (en) 2006-08-09
NZ547195A (en) 2010-06-25
CA2546189C (en) 2013-04-23
BRPI0416680A (pt) 2007-02-13
IL229124A0 (en) 2013-12-31
PL1686997T3 (pl) 2009-09-30
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
AU2004290902A1 (en) 2005-06-02
US8017621B2 (en) 2011-09-13
WO2005049032A1 (en) 2005-06-02
IL175578A0 (en) 2008-04-13
CN102274230A (zh) 2011-12-14
KR101153647B1 (ko) 2012-06-18
RU2405553C1 (ru) 2010-12-10
KR20060101761A (ko) 2006-09-26

Similar Documents

Publication Publication Date Title
IL229124A0 (en) Inhibitors with a mutant form of kit
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
BR0213981A (pt) Fotoiniciadores difuncionais
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
ATE414697T1 (de) Nf-kb-inhibitoren
ECSP045429A (es) Combinacion de compuestos organicos
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
NO20034056D0 (no) Proliferative sykdommer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE444296T1 (de) Analoga und prodrugs von buprenorphin
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
NO20071937L (no) Fremgangsmater og mellomprodukter for fremstilling av cysteinproteaseinhibitorer
NO20070423L (no) Ny anvendelse av peptidforbindelser for behandling av essensiell tremor og andre tremorsyndromer
EA200600465A1 (ru) Ингибиторы каспазы, содержащие изоксазолиновый цикл
DK1339407T3 (da) Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
ECSP055844A (es) Nuevos compuestos triciclicos
DE60329326D1 (de) Tace inhibitoren
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
DK1569650T3 (da) Anvendelse af levocetirizin til behandling af vedvarende rhinitis allergica
ATE426613T1 (de) Cc-chemokin-antagonisten